ArticleInternational journal of pharmaceutics2025
Development of an inhalable dry powder of mycobacteriophage D29 using thin-film freeze-drying.
Article in International journal of pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Drum Filling of Thin-Film Freeze-Dried Monoclonal Antibody Powder in UniDose Powder Nasal Spray System.Pharmaceutical research · 2025Article
- Latest Advances in Inhalable Dry Powder Bacteriophage Therapy for Pulmonary Infections.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aimed to develop a stable dry powder formulation of anti-tuberculosis mycobacteriophage D29 for pulmonary delivery using thin-film freeze-drying (TFFD), which uses rapid freezing and sublimation to generate highly aerosolizable powders. D29 is a shear-sensitive phage with a long, non-contractile tail from the family Siphoviridae, the most common morphotype for mycobacteriophages. Following a design-of-experiments approach, we first screened formulation and process variables for their influence on phage stability. Higher concentrations of trehalose and leucine and a higher drum temperature during freezing were identified as protective factors for the phage. A Box-Behnken design was then used to optimize levels of trehalose, leucine, polyvinylpyrrolidone (PVP)-K25, and the drum temperature, and a model was constructed to enable prediction of optimal formulations. The predicted optimal formulation for titer recovery did retain high phage viability after drying and could deliver 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.